Gao Fei, Zeng Donglin, Wei Helen, Wang Xuena, Ibrahim Joseph G
Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA.
Global Biostatistical Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
Stat Biosci. 2018 Aug;10(2):473-489. doi: 10.1007/s12561-016-9164-x. Epub 2016 Aug 29.
In many clinical studies, patients may experience the same type of event of interest repeatedly over time. However, the assessment of treatment effects is often complicated by the rescue medication uses due to ethical reasons. For example, in the motivating trial in studying the Immune Thrombocytopenia (ITP), when the interest lies in evaluating the treatment benefit of investigational product (IP) on reducing patient's repeated bleeding, rescue medication such as platelet transfusions may be allowed to raise platelet counts. Both the intention-to-treat analysis and treating the intermediate rescue medication as covariate tend to attenuate the treatment benefit, and the estimates can be biased if interpreted as causal. In this paper, we propose a general causal framework when intermediate rescue medications are informative. We adopt the inverse weighted estimation approach to estimate the treatment effect, where weights are constructed to reflect time-dependent medication use probabilities. The proposed estimators are shown to be asymptotically normal and are demonstrated to perform well in small-sample simulation studies. The application to the ITP studies reveals a stronger benefit of using IP in reducing bleeding.
在许多临床研究中,随着时间推移,患者可能会反复经历相同类型的感兴趣事件。然而,出于伦理原因,救援药物的使用常常使治疗效果评估变得复杂。例如,在一项针对免疫性血小板减少症(ITP)的激励试验中,当研究兴趣在于评估研究产品(IP)在减少患者反复出血方面的治疗益处时,可能会允许使用诸如血小板输注等救援药物来提高血小板计数。意向性分析以及将中间救援药物作为协变量处理往往会削弱治疗益处,并且如果将估计值解释为因果关系,可能会产生偏差。在本文中,我们提出了一个中间救援药物具有信息性时的一般因果框架。我们采用逆加权估计方法来估计治疗效果,其中权重的构建反映了随时间变化的药物使用概率。所提出的估计量被证明是渐近正态的,并且在小样本模拟研究中表现良好。在ITP研究中的应用揭示了使用IP在减少出血方面有更强的益处。